SCHEMBL4017359

SCHEMBL4017359

Cc1[nH]c2c(F)ccc(C)c2c1CCNC(=O)/C=C/c1ccccc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
LMNA P02545 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
GAA P10253 1/20 0.43
RAB9A P51151 6/20 0.41
NPC1 O15118 5/20 0.41
HPGD P15428 3/20 0.41
MAPT P10636 2/20 0.41
CYP1A2 P05177 3/20 0.40
ALDH1A1 P00352 3/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C19 P33261 2/20 0.40
RECQL P46063 2/20 0.40
JAK2 O60674 1/20 0.40
HTT P42858 1/20 0.40
PKM P14618 1/20 0.40
MMP1 P03956 1/20 0.37
POLB P06746 1/20 0.37
MMP2 P08253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4017528 0.94 MEN1 (0.49) MEN1KMT2ALMNASMN1; SMN2GAA
SCHEMBL13982583 0.92 MEN1 (0.48) MEN1KMT2ALMNASMN1; SMN2GAA
SCHEMBL13982460 0.91 MEN1 (0.47) MEN1KMT2ALMNASMN1; SMN2GAA
SCHEMBL4017822 0.91 GAA (0.55) MEN1KMT2ALMNASMN1; SMN2GAA
SCHEMBL4017825 0.90 MMP1 (0.50) MEN1KMT2ALMNASMN1; SMN2RAB9A
SCHEMBL4017363 0.89 MEN1 (0.62) MEN1KMT2ALMNASMN1; SMN2GAA
SCHEMBL4669261 0.89 ALDH1A1 (0.48) MEN1KMT2ALMNASMN1; SMN2GAA
SCHEMBL4669267 0.89 MEN1 (0.46) MEN1KMT2ALMNASMN1; SMN2GAA
SCHEMBL4755471 0.89 MEN1 (0.46) MEN1KMT2ALMNASMN1; SMN2GAA
SCHEMBL4667926 0.88 MEN1 (0.45) MEN1KMT2ALMNASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2014287-A1 Use of cinnamic acid derivatives as modulators of an EP2 receptor Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP claimed
EP-2014287-A1 Use of cinnamic acid derivatives as modulators of an EP2 receptor Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP disclosed